EUVIMEDEUVIMED entdecken
Crossref

Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics

Samantha Anderer

JAMA · 26.05.2026 · 335 (20) · 1739

DOI: 10.1001/jama.2026.6177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 26.05.2026. Verfasst von Samantha Anderer. Beteiligte Einrichtung: Staff Writer, Medical News, JAMA.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This Medical News article discusses findings that genetic variants may affect patients’ responses to glucagon-like peptide-1 receptor agonists such as semaglutide and tirzepatide.

Autor:innen und Institutionen

  • Staff Writer, Medical News, JAMA.

Zitieren

APA

Anderer, S. (2026). Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics. JAMA, 335(20), 1739. https://doi.org/10.1001/jama.2026.6177

Vancouver

Anderer S. Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics. JAMA. 2026;335(20):1739. doi:10.1001/jama.2026.6177

BibTeX
@article{Anderer2026,
  author = {Anderer, Samantha},
  title = {Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {20},
  pages = {1739},
  doi = {10.1001/jama.2026.6177}
}
Kostenlos starten →